University of Oviedo

Nebulized colistimethate sodium showed mixed results in bronchiectasis and Pseudomonas aeruginosa infections, with PROMIS-I showing reduced exacerbation rates (RR 0.61) and PROMIS-II showing no difference (RR 1.00). COVID-19 disruptions in PROMIS-II were identified as the cause for the differing outcomes. A meta-analysis supported colistimethate sodium's efficacy in reducing exacerbation rates (RR 0.65). Despite inconsistent trial results, inhaled antibiotics for bronchiectasis have received conditional endorsement in guidelines.